Introduction: Prior Approval Supplement (PAS) MCQs With Answer is designed for M.Pharm students specializing in Documentation & Regulatory Writing who want a focused review on regulatory requirements for post-approval changes. This set of questions covers the rationale, scope, examples, regulatory pathways (e.g., PAS vs CBE), and documentation expectations required by regulatory agencies like the US FDA. The questions emphasize CMC, manufacturing site changes, formulation adjustments, labeling, stability, and when prior approval is mandatory to ensure product quality, safety, and efficacy. Use these MCQs to deepen understanding of regulatory strategy, submission types, timelines, and common pitfalls when preparing supplements for approved drug applications.
Q1. What is the primary purpose of a Prior Approval Supplement (PAS) in regulatory submissions?
- To notify the agency about minor editorial label changes
- To request approval before implementing major post-approval changes that could affect safety or efficacy
- To submit annual safety reports
- To apply for pediatric exclusivity
Correct Answer: To request approval before implementing major post-approval changes that could affect safety or efficacy
Q2. Which of the following examples most likely requires a PAS for an approved drug product?
- Typographical correction in package insert
- Minor change in manufacturing equipment within same facility causing no impact on product quality
- Change in the formulation that alters bioavailability
- Change in marketing contact phone number
Correct Answer: Change in the formulation that alters bioavailability
Q3. Which regulatory pathway is typically used when a sponsor wishes to make a major change immediately upon approval without waiting for agency approval?
- Prior Approval Supplement (PAS)
- Changes Being Effected in 30 days (CBE-30)
- Changes Being Effected (CBE-0)
- Annual Report submission
Correct Answer: Changes Being Effected (CBE-0)
Q4. Under US FDA guidance, changing the manufacturing site for a sterile injectable product where sterility assurance is impacted would typically be submitted as:
- An annual report item
- A Prior Approval Supplement (PAS)
- A labeling supplement
- A minor CBE
Correct Answer: A Prior Approval Supplement (PAS)
Q5. Which of the following is a key piece of documentation expected in a PAS for a formulation change that may affect bioavailability?
- Comparative dissolution data and bioequivalence or bridging study reports
- Only a revised label PDF
- Marketing plan and cost analysis
- Patient complaint log without analytical support
Correct Answer: Comparative dissolution data and bioequivalence or bridging study reports
Q6. For an NDA, the FDA review goal for a PAS is generally:
- Immediate approval upon submission
- Review within 6 months for major changes by default
- Same review timelines as original application with priority determined case-by-case
- No review required
Correct Answer: Same review timelines as original application with priority determined case-by-case
Q7. Which change is most appropriately submitted as a CBE-30 rather than a PAS?
- Significant formulation change that changes the route of administration
- Change in container closure components for a nonsterile dosage form with minor impact
- Change in dissolution specification increasing the limit for critical release
- Change in active moiety concentration that affects potency
Correct Answer: Change in container closure components for a nonsterile dosage form with minor impact
Q8. A sponsor wishes to introduce a new strength of an approved drug with altered excipient levels that may affect release. The appropriate submission type is:
- Annual report
- Prior Approval Supplement (PAS)
- Type II DMF update only
- CBE-0
Correct Answer: Prior Approval Supplement (PAS)
Q9. Which of these best describes an FDA PAS review outcome?
- Approval, approvable with conditions, or not approvable
- Only approval or rejection
- No formal written communication is provided
- Automatic approval after 30 days
Correct Answer: Approval, approvable with conditions, or not approvable
Q10. When changing a drug’s preservative system that could affect microbial stability, the sponsor should submit:
- An advertising supplement
- A Prior Approval Supplement (PAS) with stability and microbiological challenge data
- A minor label correction
- An annual report note only
Correct Answer: A Prior Approval Supplement (PAS) with stability and microbiological challenge data
Q11. For ANDAs (generics), what submission type is equivalent to a PAS for major post-approval changes?
- Supplement and Amendment to the ANDA (major supplement)
- Annual report only
- Patent certification
- Only a letter to the agency is required
Correct Answer: Supplement and Amendment to the ANDA (major supplement)
Q12. Which documentation is crucial in a PAS addressing a change in analytical method used for release testing?
- Validation data, method transfer results, and comparability data
- Only the method SOP without validation
- Marketing authorization in another country
- Facility floor plans only
Correct Answer: Validation data, method transfer results, and comparability data
Q13. A sponsor implements a change under a PAS that impacts impurity profile. Which regulatory element must be included?
- Impurity identification, qualification, and toxicological risk assessment
- Only a revised batch record
- Only a new label with impurity limits
- Only supplier invoices
Correct Answer: Impurity identification, qualification, and toxicological risk assessment
Q14. What is a comparability protocol and how does it relate to PAS?
- A pre-agreed plan describing how specific changes will be evaluated; following it can allow post-change reporting without PAS if conditions are met
- A marketing plan for product launch
- A document unrelated to regulatory submissions
- An annual financial disclosure
Correct Answer: A pre-agreed plan describing how specific changes will be evaluated; following it can allow post-change reporting without PAS if conditions are met
Q15. Which change to labeling typically requires prior approval rather than a CBE?
- Minor editorial wording corrections
- Adding new contraindications or safety warnings based on clinical findings
- Changing the marketer’s address
- Updating storage temperature within approved range
Correct Answer: Adding new contraindications or safety warnings based on clinical findings
Q16. When a PAS is submitted for a major sterilization process change, which of the following is most likely expected?
- Process validation data, sterility assurance level, and package-sterilization interaction data
- Only a summary statement without data
- Only a change in the batch record template
- Only marketing authorization letters
Correct Answer: Process validation data, sterility assurance level, and package-sterilization interaction data
Q17. Which of the following is TRUE regarding PAS and stability commitments?
- PAS never requires stability data
- PAS may require supportive stability data or post-change commitments if long-term data are not yet available
- Stability data should only be submitted in annual reports
- Stability data is optional and never scrutinized
Correct Answer: PAS may require supportive stability data or post-change commitments if long-term data are not yet available
Q18. If a sponsor wants to increase batch size significantly for an oral solid dose where dissolution may change, the appropriate action is:
- Implement the change and record it in next annual report
- Submit a Prior Approval Supplement (PAS) with scale-up comparability data
- Use a Type II DMF update only
- Make the change under a labeling supplement
Correct Answer: Submit a Prior Approval Supplement (PAS) with scale-up comparability data
Q19. Which regulatory citation or guidance is commonly referenced when preparing a PAS for CMC changes in the U.S.?
- 21 CFR Part 314 and FDA guidance on Quality Considerations and Changes to an Approved NDA/BLA
- International tax law
- Local building codes
- Pharmacovigilance only, unrelated to CMC
Correct Answer: 21 CFR Part 314 and FDA guidance on Quality Considerations and Changes to an Approved NDA/BLA
Q20. Which statement about electronic submission of a PAS (eCTD) is correct?
- eCTD format is optional and rarely used for PAS
- Most regulatory agencies, including FDA, expect PAS submissions in eCTD format with appropriate module organization and cross-references
- PAS must be submitted only in paper and cannot be electronic
- eCTD submissions do not require module 3 content for CMC changes
Correct Answer: Most regulatory agencies, including FDA, expect PAS submissions in eCTD format with appropriate module organization and cross-references
